SHBG

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Retrieved on: 
Wednesday, March 27, 2024
Multiple, Professor, ETV, SAN, Patient, Hepatology, Southern Medical University, SHBG, Doctor of Science, University, Doctor of Philosophy, MBBS, MASH, MBA, Science, Therapy, Hepatitis, Part, Division, University of Hong Kong, Infection, CHB, Pharmaceutical industry

The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.

Key Points: 
  • The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.
  • “We are pleased to present these additional Phase 1 data for ALG-055009 and ALG-000184 at APASL 2024.
  • We continue to believe our molecule has the potential to be best-in-class,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • “In addition, the three ALG-000184 oral presentations demonstrate a consistent effect in the reduction of key viral markers.

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Retrieved on: 
Thursday, December 7, 2023
Liver, AASLD, Multiple, NASH, SHBG, HBV, MBA, SAN, Therapy, Thyroid, THR, Doctor of Philosophy, HBeAg, CccDNA, Safety, Patient, Pharmacology, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-β) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from December 3 – 7, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-β) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from December 3 – 7, 2023.
  • The presentations can be found on the “Scientific Presentations & Conferences” section of the Aligos website ( www.aligos.com ).
  • “We’re greatly encouraged by the substantial and consistent reductions in HBV viral markers observed during prolonged dosing of ALG-000184 and are grateful for the opportunity to share these results with the scientific community at the Hep-DART 2023 meeting,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics.
  • As presented at AASLD, ALG-055009 appears to have best-in-class potential.

Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
THR, Hepatology, Safety, Magnetic resonance imaging, Steatosis, AASLD, Liver, FXR, Clinical trial, Fatty liver disease, CT1, Patient, Week, Obesity, Houston Methodist Hospital, Non-alcoholic fatty liver disease, Bangladesh Technical Education Board, SHBG, MRI, Biomarker, NASH, DUET, Fibrosis, Pharmaceutical industry, Boston

FOSTER CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced the late-breaking oral presentation of top-line data from its Phase 2a DUET clinical trial of TERN-501, an investigational orally administered thyroid hormone receptor-β (THR-β) agonist for the treatment of NASH. TERN-501 was evaluated alone and in combination with the Company’s liver-distributed farnesoid X receptor (FXR) agonist TERN-101. These data will be presented at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), on Monday, November 13 at 2:00 p.m. ET in Boston, Massachusetts.

Key Points: 
  • TERN-501 was evaluated alone and in combination with the Company’s liver-distributed farnesoid X receptor (FXR) agonist TERN-101.
  • These data will be presented at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), on Monday, November 13 at 2:00 p.m.
  • “These top-line data of TERN-501 are encouraging, with significant reductions in key biomarkers including liver fat content, MRI-PDFF, and cT1, a marker of fibro-inflammation.
  • Terns will host an investor reception event during The Liver Meeting in Boston on Monday, November 13 at 4:00 p.m.

Marius Pharmaceuticals Announces KYZATREX® (CIII testosterone undecanoate capsules) HERO Campaign, Empowering Men To 'Be the Hero of Your Life Again'

Retrieved on: 
Wednesday, December 6, 2023
WCS, Hypertension, Adolescence, Testosterone, HERO, Prevalence, Ageing, Testicular cancer, Hero, Hypogonadism, Patient, Prostate cancer, Health, Veteran, Cancer, SHBG, Site, Physician, Androgen, Overalls, Pharmaceutical industry

RALEIGH, N.C., Dec. 6, 2023 /PRNewswire/ -- Marius Pharmaceuticals , a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announces the launch of its KYZATREX® HERO campaign that aims to empower men to "Be the Hero of Your Life Again."

Key Points: 
  • RALEIGH, N.C., Dec. 6, 2023 /PRNewswire/ -- Marius Pharmaceuticals , a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announces the launch of its KYZATREX® HERO campaign that aims to empower men to "Be the Hero of Your Life Again."
  • KYZATREX is an oral prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions.
  • The advertising campaign seeks to educate patients who are appropriate candidates for treatment and their physicians on how KYZATREX can help men restore testosterone levels to reinvigorate their natural vitality.
  • In a clinical efficacy study of 127 hypogonadal patients, 96% of patients taking KYZATREX had normal testosterone levels at Day 90.

Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH

Retrieved on: 
Tuesday, August 8, 2023
FXR, Houston Methodist Hospital, Therapy, NASH, Week, Steatohepatitis, Triglyceride, Liver disease, CT1, SHBG, TERN, Bangladesh Technical Education Board, Medicine, Plasma, Fibrosis, Patient, DUET, LDL, Liver, Apolipoprotein B, FDA, GI, Safety, Medical imaging, Pharmaceutical industry

FOSTER CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today reported positive top-line results from the Phase 2a DUET clinical trial of TERN-501, an orally-administered thyroid hormone receptor-beta (THR-β) agonist, administered as a monotherapy or in combination with TERN-101, a liver-distributed farnesoid X receptor (FXR) agonist, for the treatment of NASH.

Key Points: 
  • TERN-501 monotherapy demonstrated improvement or trends toward improvement in plasma lipid parameters, such as LDL-C, HDL-C, triglycerides, and apolipoprotein B (ApoB).
  • TERN-501 was generally well tolerated, with adverse events (AEs) being generally mild and evenly distributed across all arms, including placebo.
  • TERN-101 safety and tolerability findings were generally consistent with the Phase 2a LIFT trial.
  • A replay of the call will also be available on the Events page of the Investor Relations section of the Terns website for 30 days.

HealthEd Academy Reports On The Latest Ketogenic Diet Study And Its Link To Boosting Testosterone By 25%

Retrieved on: 
Tuesday, December 20, 2022
Manchester Health Academy, Serum, Insulin, Journal, Human, Research, Hypogonadism, Knowledge, Wilson, Waist, Power, Blood, SHBG, Testosterone, Male, BMI, The Journal of Strength and Conditioning Research, Weight loss, Health, Athlete, Dietary supplement, Online shopping, Soft drink, Strength

The latest healthcare news that HealthEd Academy is reporting on is the peer-reviewed study published by Wiley’s Andrology Journal on December 2, 2022, which states that a ketogenic diet increases testosterone levels in obese males by up to 25%.

Key Points: 
  • The latest healthcare news that HealthEd Academy is reporting on is the peer-reviewed study published by Wiley’s Andrology Journal on December 2, 2022, which states that a ketogenic diet increases testosterone levels in obese males by up to 25%.
  • These findings suggest that a low-calorie keto diet can lead to rapid improvements in total testosterone levels associated with weight loss in male obese non-diabetic subjects.
  • The study, ‘Very low-calorie ketogenic diet rapidly augments testosterone levels in non-diabetic obese subjects’ by Angelo Cignarelli et al., that HealthEd Academy is sharing, followed 22 obese males who stuck to a ketogenic diet for 28 days.
  • 34, the study corroborates with the findings reported by Cignarelli as Wilson found that a ketogenic diet (compared to the standard Western diet) significantly increased the men’s total testosterone levels by up to 118ng/dL after 11 weeks.

Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, IND, MRI, CML, FXR, GIPR, BCR-ABL, Research and development, Fatty liver disease, NASH, Webcast, CT1, AASLD, THR, TKI, R, BCR, Obesity, Safety, Time, Pharmacokinetics, ABL, Clinical trial, Conference, Patient, Discovery, Allosteric regulation, Administration, Tern, Acute leukemia, SHBG, Pharmaceutical industry, Air cargo

The third quarter marked an exciting period for Terns, as we continued to accelerate development of our three lead programs in indications with large unmet need.

Key Points: 
  • The third quarter marked an exciting period for Terns, as we continued to accelerate development of our three lead programs in indications with large unmet need.
  • We look forward to continued momentum in 2023 and multiple important milestones for Terns product candidates next year, said Sen Sundaram, chief executive officer at Terns.
  • A live webcast will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com .
  • A replay of the webcast will be archived on Terns website for 30 days following the presentation.

Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022

Retrieved on: 
Friday, November 4, 2022
Company, Tern, Research, SHBG, BCR, Obesity, Risk, GLOBE, NASH, Triglyceride, Safety, American Association of Neuromuscular & Electrodiagnostic Medicine, Fibrosis, Fatty liver disease, Itch, Non-alcoholic fatty liver disease, Terminology, Institute of Liver and Biliary Sciences, Liver disease, AASLD, FXR, THR, DUET, Pharmacology, Annual report, Clinical trial, LDL, Metabolism, Inflammation, Liver, MRI, Lipid metabolism, Gene, Association, Patient, Pharmacokinetics, American Association, Pharmaceutical industry

FOSTER CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that the company is presenting positive clinical data from its Phase 1 study of TERN-501, a thyroid hormone receptor beta (THR-β) agonist in development for the treatment of NASH. The results are being highlighted in a poster presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 4-8, 2022.

Key Points: 
  • The results are being highlighted in a poster presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 4-8, 2022.
  • Results showed that among the 24 treated participants TERN-501 was generally well tolerated and exhibited dose-dependent pharmacokinetics with low variability.
  • Terns will review the ongoing Phase 2a DUET trial ( NCT05415722 ) design and objectives in a second presentation at The Liver Meeting.
  • Terns reported positive top-line single-ascending and multiple-ascending dose (SAD/MAD) data from Phase 1 proof of concept clinical trial in November 2021.

Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

Retrieved on: 
Monday, November 15, 2021
Synthetic, Safety, PK, Hepatitis, PD, Director, HDL, Fatty liver disease, Clinical trial, LDL, R, Research and development, N.U.D.E.@ Natural Ultimate Digital Experiment, AASLD, Administration, Aviation parts tag, Digital, GGT, AstraZeneca, MRI, ALT, Board, Liver, NASH, Tern, GLOBE, Itch, Week, Fibrosis, Diabetes, Patient, Head, CT1, Peptide, SHBG, Drug development, Obesity, Medical imaging, Fine chemical, Pharmaceutical industry, Coal

FOSTER CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today reported financial results for the third quarter ended September 30, 2021 and corporate highlights.

Key Points: 
  • -Positive top-line data from TERN-501 (THR-) demonstrated clinical proof of concept, enabling the planned initiation of NASH trial in 1H 2022
    FOSTER CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today reported financial results for the third quarter ended September 30, 2021 and corporate highlights.
  • Recent positive clinical data for TERN-101 and TERN-501 presented at AASLD validate part one of Terns strategy, which is demonstrating monotherapy proof of concept.
  • We look forward to the top-line data readout from the AVIATION Trial of TERN-201 in the first quarter of 2022, which could mark our third clinical candidate with promising monotherapy data, said Senthil Sundaram, chief executive officer at Terns.
  • Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2024.

Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501

Retrieved on: 
Tuesday, November 9, 2021
Liver disease, Safety, PD, Fatty liver disease, LDL, Steatosis, Terminology, Disease, Food, FXR, N.U.D.E.@ Natural Ultimate Digital Experiment, Risk, SAD, AASLD, Cardiotoxicity, COVID-19, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Triglyceride, Annual report, Liver, Chronic liver disease, NASH, Company, Tern, VAP-1, Metabolism, DDI, Fibrosis, THR, Patient, Fast Track, Head, FDA, SHBG, Pharmaceutical industry

FOSTER CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today reported positive top-line results from a Phase 1 clinical trial of TERN-501, a thyroid hormone receptor beta (THR-β) agonist in development for the treatment of patients with NASH.

Key Points: 
  • Additional data from the SAD cohorts will be presented at AASLD The Liver Meeting Digital Experience in November 2021.
  • Preliminary PK results support the co-administration of TERN-101 and TERN-501 in NASH patients, with no apparent need for dose adjustment.
  • The TERN-501 proof of concept data are highly encouraging and indicate potent liver target engagement and the potential for broad benefits in NASH patients.
  • Terns pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR- agonist, and a preclinical GLP-1 receptor agonist program.